Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

IVVD has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Invivyd in a research note on Monday, February 24th. Morgan Stanley decreased their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Invivyd presently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Trading Down 0.1 %

Shares of NASDAQ IVVD opened at $0.74 on Thursday. Invivyd has a 12-month low of $0.35 and a 12-month high of $4.74. The stock has a market cap of $88.28 million, a PE ratio of -0.38 and a beta of 0.09. The company has a 50-day moving average of $0.98 and a 200 day moving average of $0.87.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $13.57 million. On average, sell-side analysts forecast that Invivyd will post -1.64 EPS for the current fiscal year.

Insider Activity

In other news, Director Terrance Mcguire sold 75,776 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.45, for a total value of $34,099.20. Following the transaction, the director now owns 3,492,498 shares of the company’s stock, valued at $1,571,624.10. This represents a 2.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 246,138 shares of company stock valued at $120,902 in the last quarter. Insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Several hedge funds have recently bought and sold shares of IVVD. State Street Corp lifted its stake in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares in the last quarter. Barclays PLC lifted its stake in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after acquiring an additional 222,375 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Invivyd during the 4th quarter worth about $74,000. Finally, Jane Street Group LLC lifted its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after acquiring an additional 87,358 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.